370 related articles for article (PubMed ID: 22592345)
1. [Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].
Chronopoulos A; Pleyer U; Mockenhaupt M
Klin Monbl Augenheilkd; 2012 May; 229(5):534-9. PubMed ID: 22592345
[TBL] [Abstract][Full Text] [Related]
2. [Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].
Chronopoulos A; Mockenhaupt M; Pleyer U
Ophthalmologe; 2021 May; 118(5):519-532. PubMed ID: 33725172
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications.
Sotozono C; Ueta M; Koizumi N; Inatomi T; Shirakata Y; Ikezawa Z; Hashimoto K; Kinoshita S
Ophthalmology; 2009 Apr; 116(4):685-90. PubMed ID: 19243825
[TBL] [Abstract][Full Text] [Related]
4. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
Tan SK; Tay YK
Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
[TBL] [Abstract][Full Text] [Related]
5. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Harr T; French LE
Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
[TBL] [Abstract][Full Text] [Related]
8. A 2-year-old girl with Stevens--Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulin.
Arca E; Köse O; Erbil AH; Nişanci M; Akar A; Gür AR
Pediatr Dermatol; 2005; 22(4):317-20. PubMed ID: 16060867
[TBL] [Abstract][Full Text] [Related]
9. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy.
De Rojas MV; Dart JK; Saw VP
Br J Ophthalmol; 2007 Aug; 91(8):1048-53. PubMed ID: 17314145
[TBL] [Abstract][Full Text] [Related]
10. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management.
Chang YS; Huang FC; Tseng SH; Hsu CK; Ho CL; Sheu HM
Cornea; 2007 Feb; 26(2):123-9. PubMed ID: 17251797
[TBL] [Abstract][Full Text] [Related]
11. Stevens-Johnson syndrome and toxic epidermal necrolysis: oncologic considerations.
Hockett KC
Clin J Oncol Nurs; 2004 Feb; 8(1):27-30, 55. PubMed ID: 14983759
[TBL] [Abstract][Full Text] [Related]
12. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
Sane SP; Bhatt AD
J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse reactions to valdecoxib distinct from Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ziemer M; Wiesend CL; Vetter R; Weiss J; Blaschke S; Norgauer J; Mockenhaupt M
Arch Dermatol; 2007 Jun; 143(6):711-6. PubMed ID: 17576936
[TBL] [Abstract][Full Text] [Related]
14. Critical factors differentiating erythema multiforme majus from Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN).
Watanabe R; Watanabe H; Sotozono C; Kokaze A; Iijima M
Eur J Dermatol; 2011; 21(6):889-94. PubMed ID: 21873140
[TBL] [Abstract][Full Text] [Related]
15. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children.
Finkelstein Y; Soon GS; Acuna P; George M; Pope E; Ito S; Shear NH; Koren G; Shannon MW; Garcia-Bournissen F
Pediatrics; 2011 Oct; 128(4):723-8. PubMed ID: 21890829
[TBL] [Abstract][Full Text] [Related]
16. [Stevens-Johnson syndrome and toxic epidermal necrolysis].
Oliveira A; Sanches M; Selores M
Acta Med Port; 2011 Dec; 24 Suppl 4():995-1002. PubMed ID: 22863510
[TBL] [Abstract][Full Text] [Related]
17. [Clinical assessment of the risk of bacteremia and the value of skin cultures during Stevens-Johnson syndrome and toxic epidermal necrolysis].
de Prost N; Duong TA; Brun-Buisson C; Roujeau JC
Ann Dermatol Venereol; 2010 Oct; 137(10):651-2. PubMed ID: 20932449
[No Abstract] [Full Text] [Related]
18. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
[TBL] [Abstract][Full Text] [Related]
19. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options.
Worswick S; Cotliar J
Dermatol Ther; 2011; 24(2):207-18. PubMed ID: 21410610
[TBL] [Abstract][Full Text] [Related]
20. [Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: retrospective study of 89 cases].
Saka B; Kombaté K; Mouhari-Toure A; Akakpo S; Tchangaï-Walla K; Pitché P
Med Trop (Mars); 2010 Jun; 70(3):255-8. PubMed ID: 20734593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]